AI drug developer Absci has reached a partnership with Oracle and AMD
Artificial intelligence drug developer Absci announced a collaboration with Oracle and AMD to accelerate the process of generative AI-driven drug discovery. The company's drug discovery platform will utilize Oracle's AI infrastructure and AMD's latest hardware
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments